24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Marine Microalgae with Anti-Cancer Properties

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cancer is the leading cause of death globally and finding new therapeutic agents for cancer treatment remains a major challenge in the pursuit for a cure. This paper presents an overview on microalgae with anti-cancer activities. Microalgae are eukaryotic unicellular plants that contribute up to 40% of global primary productivity. They are excellent sources of pigments, lipids, carotenoids, omega-3 fatty acids, polysaccharides, vitamins and other fine chemicals, and there is an increasing demand for their use as nutraceuticals and food supplements. Some microalgae are also reported as having anti-cancer activity. In this review, we report the microalgal species that have shown anti-cancer properties, the cancer cell lines affected by algae and the concentrations of compounds/extracts tested to induce arrest of cell growth. We also report the mediums used for growing microalgae that showed anti-cancer activity and compare the bioactivity of these microalgae with marine anticancer drugs already on the market and in phase III clinical trials. Finally, we discuss why some microalgae can be promising sources of anti-cancer compounds for future development.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: not found

          Microalgae biorefinery: High value products perspectives.

          Microalgae have received much interest as a biofuel feedstock in response to the uprising energy crisis, climate change and depletion of natural sources. Development of microalgal biofuels from microalgae does not satisfy the economic feasibility of overwhelming capital investments and operations. Hence, high-value co-products have been produced through the extraction of a fraction of algae to improve the economics of a microalgae biorefinery. Examples of these high-value products are pigments, proteins, lipids, carbohydrates, vitamins and anti-oxidants, with applications in cosmetics, nutritional and pharmaceuticals industries. To promote the sustainability of this process, an innovative microalgae biorefinery structure is implemented through the production of multiple products in the form of high value products and biofuel. This review presents the current challenges in the extraction of high value products from microalgae and its integration in the biorefinery. The economic potential assessment of microalgae biorefinery was evaluated to highlight the feasibility of the process.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Biologically Active Metabolites Synthesized by Microalgae

            Microalgae are microorganisms that have different morphological, physiological, and genetic traits that confer the ability to produce different biologically active metabolites. Microalgal biotechnology has become a subject of study for various fields, due to the varied bioproducts that can be obtained from these microorganisms. When microalgal cultivation processes are better understood, microalgae can become an environmentally friendly and economically viable source of compounds of interest, because production can be optimized in a controlled culture. The bioactive compounds derived from microalgae have anti-inflammatory, antimicrobial, and antioxidant activities, among others. Furthermore, these microorganisms have the ability to promote health and reduce the risk of the development of degenerative diseases. In this context, the aim of this review is to discuss bioactive metabolites produced by microalgae for possible applications in the life sciences.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.

              Ecteinascidins are marine natural products consisting of two or three linked tetrahydroisoquinoline subunits and an active carbinolamine functional group. Their potent antiproliferative activity against a variety of tumor cells makes them attractive candidates for development as anticancer agents. The lead compound, Yondelis (trabectedin, ET-743) is the first marine anticancer agent approved in the European Union for patients with soft tissue sarcoma (STS). Positive results of a large randomized Phase III clinical trial in ovarian cancer have recently been presented. The low amounts present in its natural source, the tunicate Ecteinascidia turbinata, made it necessary to develop efficient synthetic procedures. The original total synthesis is reviewed as well as a new semisythetic process from the readily available cynosafracin B, which has solved the supply problem.
                Bookmark

                Author and article information

                Journal
                Mar Drugs
                Mar Drugs
                marinedrugs
                Marine Drugs
                MDPI
                1660-3397
                15 May 2018
                May 2018
                : 16
                : 5
                : 165
                Affiliations
                Department of Integrative Marine Ecology, Stazione Zoologica Anton Dohrn, 80121 Naples, Italy; kevin.martinez@ 123456szn.it (K.A.M.A.); chiara.lauritano@ 123456szn.it (C.L.); romano@ 123456szn.it (G.R.)
                Author notes
                [* ]Correspondence: adrianna.ianora@ 123456szn.it ; Tel.: +39-081-583-3246
                Author information
                https://orcid.org/0000-0003-4580-9594
                Article
                marinedrugs-16-00165
                10.3390/md16050165
                5983296
                29762545
                caa7e842-7fa4-4feb-a9fc-67a7ec93056c
                © 2018 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 23 April 2018
                : 12 May 2018
                Categories
                Review

                Pharmacology & Pharmaceutical medicine
                marine biotechnology,microalgae,anti-cancer
                Pharmacology & Pharmaceutical medicine
                marine biotechnology, microalgae, anti-cancer

                Comments

                Comment on this article